Opendata, web and dolomites

BiopSense SIGNED

Proof of concept and pre-commercialisation of personalised liquid biopsies in cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiopSense project word cloud

Explore the words cloud of the BiopSense project. It provides you a very rough idea of what is the project "BiopSense" about.

cog    closest    commercialization    partnering    polymorphism    agena    chip    mass    accuracy    sensitive    blood    biopsies    panel    nucleotide    shield    lab    spin    screening    local    flexible    options    trl    cheaper    personalized    investors    steering    care    upgrading    automated    biomarkers    treatment    biotech    ipr    personalised    diagnostics    started    components    allowed    consultation    negotiations    licensors    health    post    determined    device    cancer    ultraseek    invention    consist    40    oncology    price    international    period    business    innovation    operation    service    prep    preparation    competing    spectrometric    point    convention    licensing    university    clarified    verified    boosting    designing    group    medication    detection    follow    competitor    patent    market    complete    single    customized    kit    liquid    centers    extremely    combined    transferring    conferences    presented    investor    companies    erc    sensitivity    continue    platform    medical    chemistry    panels    either    hospitals    extended    diagnostic   

Project "BiopSense" data sheet

The following table provides information about the project.

Coordinator
JYVASKYLAN YLIOPISTO 

Organization address
address: SEMINAARINKATU 15
city: JYVASKYLA
postcode: 40100
website: http://www.jyu.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 149˙999 €
 EC max contribution 149˙999 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    JYVASKYLAN YLIOPISTO FI (JYVASKYLA) coordinator 149˙999.00

Map

 Project objective

Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOPSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOPSENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

GTBB (2019)

General theory for Big Bayes

Read More